AFALA is an original and affordable drug for the treatment of chronic prostatitis.
Afala in the complex therapy of chronic prostatitis helps to reduce inflammation and swelling in the prostate gland, thereby normalizing its functional state, improves urodynamics, normalizes the tone of the lower urinary tract and helps to reduce dysuric disorders.
active ingredients: antibodies to the prostate-specific antigen affinity purified: a mixture of homeopathic dilutions C12, C30, C200 - 0.003g,
excipients: lactose, microcrystalline cellulose, magnesium stearate.
The active component of Afala are antibodies to the prostate-specific antigen. Taking into account modern ideas about the pathogenesis of BPH (benign prostatic hyperplasia) and the possible role of prostate-specific antigen in the regulation of the proliferative activity of prostate cells, the most likely mechanism of the pharmacological action of the drug is the modification of the functional activity of endogenous prostate-specific antigen.
Reduces the phenomena of edema and inflammation in the prostate gland, normalizes its functional state during inflammation. Improves urodynamics, reduces the volume of residual urine, normalizes the tone of the lower urinary tract, helps to reduce dysuric disorders (frequent urge to urinate, including at night; difficulty urinating; pain or discomfort in the perineum).
- benign prostatic hyperplasia of the I and II stages, accompanied by dysuric disorders
- acute and chronic prostatitis, accompanied by dysuric disorders (as part of complex therapy, together with anti-inflammatory and antibacterial agents).
1-2 tablets up to 4 times a day without regard to food intake. The tablet should be kept in the mouth without swallowing until completely dissolved.
Recommended duration of treatment: up to 16 weeks.
If necessary, it is possible to conduct a second course of treatment after 1.5 - 2 months on the recommendation of a doctor.
When using the drug according to the indicated indications and in the indicated dosages, no side effects were detected.
- increased individual sensitivity to the components of the drug
- age up to 18 years (due to lack of experience in clinical use).
The composition of the drug includes lactose, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or congenital lactose deficiency.
- in case of accidental overdose, dyspeptic phenomena are possible due to the excipients included in the dosage form.
In a dry, dark place, at a temperature not exceeding 25ºС.
Keep out of the reach of children.
Shelf life - 3 years
Do not use after the expiration date.
Afala in the complex therapy of chronic prostatitis helps to reduce inflammation and swelling in the prostate gland, thereby normalizing its functional state, improves urodynamics, normalizes the tone of the lower urinary tract and helps to reduce dysuric disorders.
One tablet contains
active ingredients: antibodies to the prostate-specific antigen affinity purified: a mixture of homeopathic dilutions C12, C30, C200 - 0.003g,
excipients: lactose, microcrystalline cellulose, magnesium stearate.
Pharmacological properties
The active component of Afala are antibodies to the prostate-specific antigen. Taking into account modern ideas about the pathogenesis of BPH (benign prostatic hyperplasia) and the possible role of prostate-specific antigen in the regulation of the proliferative activity of prostate cells, the most likely mechanism of the pharmacological action of the drug is the modification of the functional activity of endogenous prostate-specific antigen.
Reduces the phenomena of edema and inflammation in the prostate gland, normalizes its functional state during inflammation. Improves urodynamics, reduces the volume of residual urine, normalizes the tone of the lower urinary tract, helps to reduce dysuric disorders (frequent urge to urinate, including at night; difficulty urinating; pain or discomfort in the perineum).
Indications for use
- benign prostatic hyperplasia of the I and II stages, accompanied by dysuric disorders
- acute and chronic prostatitis, accompanied by dysuric disorders (as part of complex therapy, together with anti-inflammatory and antibacterial agents).
Dosage and administration
1-2 tablets up to 4 times a day without regard to food intake. The tablet should be kept in the mouth without swallowing until completely dissolved.
Recommended duration of treatment: up to 16 weeks.
If necessary, it is possible to conduct a second course of treatment after 1.5 - 2 months on the recommendation of a doctor.
Side effects
When using the drug according to the indicated indications and in the indicated dosages, no side effects were detected.
Contraindications
- increased individual sensitivity to the components of the drug
- age up to 18 years (due to lack of experience in clinical use).
Special instructions
The composition of the drug includes lactose, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or congenital lactose deficiency.
Overdose
- in case of accidental overdose, dyspeptic phenomena are possible due to the excipients included in the dosage form.
Storage conditions
In a dry, dark place, at a temperature not exceeding 25ºС.
Keep out of the reach of children.
Shelf life - 3 years
Do not use after the expiration date.
Related Products
Avara Pharmaceutical Technologies Inc. (USA)
Vezomni 6 mg / 0.4 mg 30s modified release tablets
$85.00
